ZD1839: Targeting the epidermal growth factor receptor in cancer therapy

Expert Opinion on Investigational Drugs

Volumn 11, Issue 6, 2002, Pages 837-849

  Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Epidermal growth factor receptor; Epidermal growth factor receptor tyrosine kinase inhibitor; Iressa; ZD1839

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLUOROURACIL; GEFITINIB; IRINOTECAN; MESSENGER RNA; MONOCLONAL ANTIBODY; ORTATAXEL; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN C FOS; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P27; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; TAXANE DERIVATIVE; TOPOTECAN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL MODIFICATION; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NAUSEA; NONHUMAN; PROSTATE TUMOR; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; TOXICITY TESTING; VOMITING; ADULT; AGED; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SAFETY;

ADULT; AGED; AGED, 80 AND OVER; ANIMAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DEVICE APPROVAL; FEMALE; HUMAN; MALE; MIDDLE AGE; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; ANIMALS; HUMANS; MIDDLE AGED;

EID: 0036016095     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.6.837     Document Type: Article

References (58)

1. Cancer burden in the year 2000. The global picture
2. Kinase inhibitors in cancer therapy: A look ahead
3. Regulation of signal transduction and signal diversity by receptor oligomerization
4. EGF receptor
5. New technologies in epidermal growth factor receptor-targeted cancer therapy
6. Epidermal growth factor-related peptides and their receptors in human malignancies
7. The epidermal growth factor receptor and its inhibition in cancer therapy
8. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
9. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
10. Phase I trial of chimerized anti-epidermal growth factor receptor (Anti-EGFRr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies
11. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to chemotherapy
12. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
13. Protein kinase inhibitors: The tyrosine-specific protein kinases
14. Tyrosine kinase inhibition: An approach to drug development
15. Protein tyrosine kinase inhibitors as novel therapeutic agents
16. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors
17. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
18. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
19. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
20. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
21. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
22. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
23. 6-Amino-4-(3-methyiphenylamino)-quinazoline: An EGF receptor tyrosine kinase inhibitor - With activity in a range of human tumour xenografts
24. ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumour growth inhibition
25. Kip1 inducing G1 arrest and enhancing the antitumour effect of interferon α
26. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by receptor treatments
27. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
28. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer
29. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
30. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
31. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839
32. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 ('Iressa') an inhibitor of EGFR tyrosine kinase does note require high levels of expression of EGFR
33. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
34. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)
35. Potentiation of cytotoxic drug activity in human cancer cells by ZD1839 ('Iressa') and EGFR-selective tyrosine kinase inhibitor
36. ZD1839 ('Iressa') an EGFR-TKI, potentiates radiation/ chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines
37. Combination of ZD1839 ('Iressa'), and EGFR-TKI, and radiotherapy increases antitumour efficacy in a human colon cancer xenograft model
38. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer
39. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity
40. ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Pharmacokinetics in a Phase I study of patients with advanced cancer
41. Final results of a phase I intermittent dose-escalation trial of ZD1839 'Iressa' in Japanese patients with various solid tumours
42. ZD1839, a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor), is well tolerated and active in patients with solid malignant tumours: Results of a Phase I trial
43. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
44. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: Evidence of activity and good tolerability
45. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a Phase I study
46. A Phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours
47. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 ('Iressa'). A selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
48. The selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: Results of a Phase I trial
49. ZD1839 ('Iressa') in patients with non-small-cell lung cancer
50. Growth factors and their receptors: New targets for prostate cancer therapy
51. Pharmacodynamic studies of the EGF receptor inhibitor ZD1839 ('Iressa') in skin from cancer patients: Histopathalogic and molecular consequences of receptor inhibition
52. Epidermal growth factor receptor tyrosine kinase inhibitor, ZD1839 ('Iressa'), in combination with 5-fluorouracil and leucovorin, in advanced colorectal cancer
53. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with Carboplatin (C) and Paclitaxel (P) in previously Non-Small Cell Lung Cancer (NSCLC)
54. Combination therapy with ZD1839 ('Iressa'), an orally active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), gemcitabine and cisplatin, in patients with advanced solid tumours: Results on tolerability, efficacy and pharmacokinetics
55. Initial results from a Phase II trial of ZD1839 (Iressa) as a second and third-line monotherapy for patients with advanced Non-Small Cell Lung Cancer (IDEAL I)
56. Phase II study of ZD1839 ('Iressa') in recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck
57. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention
58. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast